Wallace, Eli M.

Targeting renal cell carcinoma with a HIF-2 antagonist

Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 709

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., et al. (2016) · Nature

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 451

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 393

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research

Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment

Cited by 336

3-[(1 S ,2 S ,3 R )-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma

Xu, R., Wang, K., Rizzi, J. P., Huang, H., Grina, J. A., Schlachter, S. T., Wang, B., Wehn, P. M., Yang, H., Dixon, D. D., et al. (2019) · Journal of Medicinal Chemistry

Cancer, Hypoxia, and MetabolismHeterocyclic Compound Synthesis and Bioactivity

Cited by 220

Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820

Du, X., Volkov, O. A., Czerwinski, R. M., Tan, H., Huerta, C., Morton, E. R., Rizzi, J. P., Wehn, P. M., Xu, R., Nijhawan, D., et al. (2019) · Structure

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 181

A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Wang, K., Wallace, E., Josey, J. A., et al. (2016) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 7

Abstract RF02-02: BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism

Beltran, P., Dhirendra, S., Xu, R., Chen, M., Czyzyk, D., Donovan, S., Feng, S., Feng, C., Fu, L., Lightstone, F., et al. (2024) · Cancer Research

PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase Signaling

Cited by 6